Vir Biotechnology, Inc. (VIR) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
VIR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VIR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 82.9% | -682.7% | -638.9% |
| 2024 | -545.0% | -791.3% | -703.4% |
| 2023 | -564.7% | -794.0% | -713.7% |
| 2022 | 61.6% | 51.6% | 31.9% |
| 2021 | 53.1% | 38.4% | 48.3% |
Download Data
Export VIR earnings history in CSV or JSON format
Free sign-in required to download data
Vir Biotechnology, Inc. (VIR) Earnings Overview
As of May 8, 2026, Vir Biotechnology, Inc. (VIR) reported trailing twelve-month net income of -$443M, reflecting +17.5% year-over-year growth. The company earned $-3.00 per diluted share over the past four quarters, with a net profit margin of -638.9%.
Looking at the long-term picture, VIR's historical earnings data spans multiple years. The company achieved its highest annual net income of $529M in fiscal 2021.
Vir Biotechnology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), MNKD (-$24M net income, 1.7% margin), AGEN ($115,000 net income, 0.1% margin), VIR has room to improve margins relative to the peer group. Compare VIR vs REGN →
VIR Earnings vs Peers
Earnings metrics vs comparable public companies
VIR Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$438M | +16.1% | -$468M | $-3.16 | -638.9% | -682.7% |
| 2024 | -$522M | +15.1% | -$587M | $-3.83 | -703.4% | -791.3% |
| 2023 | -$615M | -219.2% | -$684M | $-4.59 | -713.7% | -794.0% |
| 2022 | $516M | -2.4% | $833M | $3.83 | 31.9% | 51.6% |
| 2021 | $529M | +277.0% | $421M | $3.96 | 48.3% | 38.4% |
| 2020 | -$299M | -71.0% | -$297M | $-2.51 | -444.1% | -441.6% |
| 2019 | -$175M | -50.7% | -$178M | $-1.62 | -24568.6% | -25032.2% |
| 2018 | -$116M | -65.9% | -$119M | $-1.20 | -13350.7% | -13674.2% |
| 2017 | -$70M | - | -$81M | $-10.02 | -46880.5% | -54696.0% |
See VIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVIR — Frequently Asked Questions
Quick answers to the most common questions about buying VIR stock.
Is VIR growing earnings?
VIR EPS is $-3.00, with earnings growth accelerating to +17.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-443M.
What are VIR's profit margins?
Vir Biotechnology, Inc. net margin is -638.9%, with operating margin at -682.7%. Below-average margins reflect competitive or cost pressures.
How consistent are VIR's earnings?
VIR earnings data spans 2017-2025. The accelerating earnings trend is +17.5% YoY. Historical data enables comparison across business cycles.